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Malignant tumors of the central nervous system (CNS) are the 10th most frequent cause of cancer mortality. Despite
the strong malignancy of some such tumors, oncogenic mutations are rarely found in classic members of the RAS
family of small GTPases. This raises the question as to whether other RAS family members may be affected in CNS
tumors, excessively activating RAS pathways. The RAS-related subfamily of GTPases is that which is most closely
related to classical Ras and it currently contains 3 members: RRAS, RRAS2 and RRAS3. While R-RAS and R-RAS2 are
expressed ubiquitously, R-RAS3 expression is restricted to the CNS. Significantly, both wild type and mutated RRAS2
(also known as TC21) are overexpressed in human carcinomas of the oral cavity, esophagus, stomach, skin and
breast, as well as in lymphomas. Hence, we analyzed the expression of R-RAS2 mRNA and protein in a wide variety
of human CNS tumors and we found the R-RAS2 protein to be overexpressed in all of the 90 CNS cancer samples
studied, including glioblastomas, astrocytomas and oligodendrogliomas. However, R-Ras2 was more strongly
expressed in low grade (World Health Organization grades I-II) rather than high grade (grades III-IV) tumors,
suggesting that R-RAS2 is overexpressed in the early stages of malignancy. Indeed, R-RAS2 overexpression was
evident in pre-malignant hyperplasias, both at the mRNA and protein levels. Nevertheless, such dramatic changes in
expression were not evident for the other two subfamily members, which implies that RRAS2 is the main factor
triggering neural transformation.
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The RAS family of small GTPases is comprised of 36
genes that encode 37 proteins. It is classified into 21 sub-
families, of which only genes in the classic RAS subfam-
ilies (HRAS, NRAS and KRAS) and RRAS2 have been seen
to carry mutations in human cancers [1]. RRAS2 (also
known as TC21) is a member of the RAS-Related (RRAS)
subfamily, which also includes RRAS (referred to hence-
forth as RRAS1) and RRAS3 (also known as MRAS) [2]. Of
the 3 members of this subfamily, R-RAS2 is the most simi-
lar to classic RAS (55-60% protein identity) [3] and this
gene has been shown to be mutated in a leiomyosarcoma
cell line, a breast cancer cell line, as well as in ovarian car-
cinoma [4-7]. However, overexpression of the wild type* Correspondence: bcubelos@cbm.uam.es
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distribution, and reproduction in any mediumform of R-RAS2 has also been frequently detected in car-
cinomas of the breast, skin, esophagus, stomach and oral
cavity. Furthermore, RRAS2 is the only RAS family mem-
ber besides classical RAS that can transform NIH-3 T3
cells. Hence, there is strong evidence that RRAS2 may be
involved in the transformation related to different types of
cancer [8-11].
The role of R-RAS2 in normal tissue has been studied in
RRas2−/− mice, which are lymphopenic due to defects in
the proliferation and survival of both T and B cells [12].
Interestingly, while mice heterozygous for the null muta-
tion (RRas2+/−) express 50% of the protein found in wild
type mice, they are phenotypically more similar to the null
knockout mice than to wild type controls [13]. In conjunc-
tion with the frequently observed overexpression of wild
type R-RAS2 in human cancer, these observations suggest
that the expression of the R-RAS2 must be tightly regu-
lated during normal tissue development and homeostasis.Med Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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identical to those of classical RAS [3], indicating that R-
RAS2 may also act in the pathways activated by classical
RAS [14]. However, while classic RAS exerts its pro-
proliferative activity via the activation of the Raf-ERK
pathway of MAP kinases, R-RAS2 appears to activate
this pathway poorly as it does not recruit Raf1 [15], al-
though it is a strong activator of the PI3K pathway
[16,17].
In the USA, malignant tumors are diagnosed in the
central nervous system (CNS) of 6.6 out of every 100,000
individuals each year, affecting mostly children and the
elderly. In developed countries they are associated with a
mortality of 2.7 per 100,000 men and women each year,
the 10th most frequent cause of mortality due to cancer
[18]. Although some of these tumors are very malignant,
mutations in classic RAS members are rare, even though
the activity of RAS effectors like PI3K may be enhanced
[19-21]. Indeed, since mutations in classic RAS genes, spe-
cifically in NRAS [22], were only detected in 2 out of 94
glioblastomas studied, we investigated whether the expres-
sion of other RAS family members may be altered in hu-
man CNS tumors. Accordingly, we studied the expression
of R-Ras2 mRNA and protein in a wide variety of human
CNS tumors. R-RAS2 was overexpressed in samples of
288 different human CNS cancers, including glioblast-
omas, astrocytomas and oligodendrogliomas. However,
R-Ras2 was more strongly expressed in low-grade (grades
I-II) tumors rather than in high grade tumors (III-IV),
suggesting that R-RAS2 is overexpressed in the early
stages of malignancy.
Methods
Western blotting
Brain tissue samples were homogenized in 1 ml of lysis
buffer (50 mM Tris [pH 8], 150 mM NaCl, 1% NP40
and a protease inhibitor cocktail [Sigma-Aldrich, USA]),
incubated on ice for 45 minutes and centrifuged at
11,000 rpm. The protein concentration of the lysate was
measured by spectrophotometry, and the proteins were
then resolved on 15% SDS-PAGE gels (80 μg/well) and
transferred to a nitrocellulose membrane. The mem-
brane was probed overnight at 4°C with a specific rabbit
antiserum against R-Ras2 (1:1000) purified with a GST-
R-Ras2 fusion protein [12]. The GST-RRAS2 fusion pro-
tein was generated by the insertion of a cDNA encoding
RRAS2 into the pGEX-4 T3 vector as recommended by
the manufacturer (Pharmacia). Antibody binding was
detected using a horseradish peroxidase-conjugated anti-
rabbit immunoglobulin G (GE Healthcare UK), which
was visualized by chemiluminescence (BioRad Labora-
tories, California, USA) after washing 3 times with 1%
TBS Tween buffer and by exposure of the membrane to
X-ray film.R-RAS2 expression
R-RAS2 expression was assessed in the commercial Brain
Tumor Screen (CC17-11-004: n = 200) and Brain Me-
dulloblastoma (CC17-11-002: n = 60) tissue microarrays
(Cybrdi). The arrays were equilibrated in 0.3 M NaCl,
0.1 M Tris–HCl [pH 7.4] containing 1% (v/v) newborn
calf serum and then probed at 4°C overnight with the spe-
cific anti-α-R-RAS2 antibody (1:100). After washing thor-
oughly, antibody binding was detected with a biotinylated
donkey anti-rabbit IgG (1 h) and then with a streptavidin-
biotinylated horseradish peroxidase complex (1 h). The ar-
rays were again washed and they were then incubated for
a further 6 minutes in 0.1 M sodium phosphate in the
presence of H2O2 (0.1 mg/ml) and diaminobenzidine
(0.5 mg/ml), producing a colorimetric reaction that was
stopped by adding 0.1 M sodium phosphate.Sample quantification
The expression of R-RAS2 in immunohistochemical (IHC)
images was evaluated by calculating the integrated density
of DAB in four equal and representative regions of interest
in each sample using ImageJ 1.44c analysis software [23]
The integrated density calculation represents the sum of
the values of the pixels in the image or selection, which is
equivalent to the product of the area and the mean gray-
scale value. For RGB images, the mean is calculated by
converting each pixel to an 8-bit grayscale using the for-
mula gray = (red + green + blue) ⁄ 3. The average density
measurements of the samples were compared with those
obtained from the controls and the results were expressed
as a percentage of the corresponding control. Each sample
was assessed by 5 independent evaluators.RT-qPCR
RNA samples
A total of 32 human samples, including normal and brain
cancer tissue samples, were analyzed to assess the expres-
sion of the genes of interest. The cancer tissues represented
4 different clinical stages and where possible, mixed ages,
genders and ethnic groups. Total RNA was isolated from
the selected tissue using Cytomyx (HBRT102, Lexington,
MA) and it was subjected to stringent quality control. The
high-quality total RNA obtained by Cytomyx was sent to
OriGene Technologies, who generated 1st strand cDNA
that was subsequently reverse transcribed using an oligo-
dT primer. The complementary DNAs (cDNAs) were syn-
thesized using a protocol optimized to generate long and
rare cDNAs, and to eliminate genomic DNA contamin-
ation. These cDNAs were transferred into Tissue qPCR
Array plates containing dried, PCR-ready, first-strand
cDNAs (Brain Cancer cDNA Array I from OriGene
Technologies).
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PCR was performed in intron-spanning assays using the
primers RRAS1 (ENSG00000126458; Fw 5′-GGCAGATC
TGGAGTCACAGC-3′, Rv 5′-ACGTTGAGACGCAGTT
TGG-3′) and RRAS3 (ENSG00000158186; Fw 5′- CAG
CTTTGAGCACGTGGA-3′, Rv 5′- CGAGGATCATCGG
GAATG-3′), designed using Probe Finder software (Roche
Applied Science, https://www.roche-applied-science.com/
sis/rtpcr/upl/index.jsp). Specific intron-spanning primers
for RRAS2 (ENSG00000133818; Fw 5′-AGCACGGCAGCT
TAAGGTAA-3′, Rv 5′-CTTTCCGTGTTGGTTCTGGT-3′)
were designed using Primer Express 2.0 software (Applied
Biosystems). The specificity of each assay was determined
by performing a BLAST search. A non-intron spanning
assay was prepared by OriGene Technologies using primers
designed against the Homo sapiens β-actin (ACTB) se-
quence (NCBI accession # NM_001101). RRAS1 and
RRAS3 were provided by Sigma Aldrich, RRAS2 by
Invitrogen and ACTB by OriGene Technologies.
The qPCR reactions were performed manually as indi-
cated by OriGene, except that the lyophilized cDNA was
diluted in twice the suggested volume of water (to evaluate
2 genes per plate instead of 1) and the reactions were
transferred to a 384-well plate. The remaining reagents
were added in the suggested proportions and qPCR was
performed on an ABI 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems), using Sybr green as a fluo-
rescent dye for detection. Relative gene expression was
normalized to ACTB expression according to the 2-ΔΔCt
method (Livak & Schmittgen, 2001), as suggested by
OriGene Technologies. This approach reduced the disper-
sion of the expression data within the biological groups
and validated this approach. The qPCR data was analyzed
with GenEx Professional 5.3.7 software (MultiD, Sweden).
Statistical analyses
All results are expressed as the mean ± standard deviation
(SD). The experimental groups were compared using a
two-sample Student’s t-test. To corroborate these statis-
tical differences, we performed an additional ANOVA test,
assembling the samples in groups according to tumor
type. The Student’s t-test and ANOVA p values are indi-
cated in the figure legends.
Exclusion criteria
Samples exhibiting necrosis or more than 20% contam-
ination with normal tissue were excluded from the ana-
lyses (C2, C9, C10, D7, D8, D9, D10, E11, E12, F4, F6
and F7 from Brain Cancer cDNA Array, sample number
178 from CC17-11-004 Array, and samples 13, 14 and
15 from CC17-01-002 Array). The tumors for which the
degree of malignancy was not established were also ex-
cluded from the study (F8, F9, F10, F11 and F12 from
Brain Cancer cDNA Array). Similarly, the samples whosevalues had a mean deviation +/− 2SD were also elimi-
nated from the study (C4, C11, D1, E1 and E12 from
Brain Cancer cDNA Array; samples numbers 22, 37, 38,
75, 85, 150 and 152 from CC17-01-002 Array). The
remaining samples were all included in the study.Results
Expression of the R-RAS2 protein in human CNS tumors
We analyzed the expression of R-RAS2 in 199 human CNS
tumor samples from 105 patients, with a wide range of
tumor types (Table 1a). The expression of the R-RAS2
protein was assessed by immunohistochemistry using the
polyclonal antiserum described previously, the specificity of
which was confirmed by immunoblotting total brain
homogenates of wild type and RRas2−/− mice (Additional
file 1: Figure S1c). R-RAS2 was overexpressed in all cancer
types and grades when compared to the 23 normal brain
tissue samples taken from patients (Figure 1, Additional file
1: Figure S1a and Additional file 2: Figure S3). Densitomet-
ric quantification revealed R-RAS2 protein expression to be
between 3- and 7-fold higher in malignant tissue (n = 170)
than in normal brain tissue (n = 23), although R-RAS2
overexpression appeared to be inversely correlated with
the tumor grade for all the tumor types analyzed. Thus,
R-RAS2 was overexpressed approximately 8-fold more in
grade III glioblastomas (n = 13) when compared to normal
tissue, while only a 4-fold increase in expression was
observed in grade IV tumors (n = 15: Figure 1). Likewise,
R-RAS2 expression increased 5-fold in grade I-II astrocyto-
mas but only 3-fold in grade III astrocytomas. Finally,
R-RAS2 expression increased approximately 7-fold in grade
I-II oligodendrogliomas (n = 9) and 4-fold in grade III tu-
mors (n = 4). Interestingly, R-RAS2 protein overexpression
was also associated with non-malignant hyperplasia in the
brain (Figure 1 and Additional file 2: Figure S3). Together,
these results suggest that R-RAS2 is overexpressed in a
wide variety of brain tumors, yet more intensely in pre-
malignant conditions. Moreover, R-RAS2 overexpression is
also more pronounced in lower grade tumors than in high-
grade glioblastomas, astrocytomas and oligodendrogliomas
(Figure 1, Additional file 1: Figure S1a and Additional file 2:
Figure S3).
An analysis of RRAS2 expression in a second array of
highly malignant CNS tumors, 57 samples from 19 pa-
tients (Table 1b), also revealed R-RAS2 overexpression in
grade IV medulloblastomas (n = 18), cerebromas (n = 9),
meningioma (n = 11), ependymomas (n = 3) and undiffe-
rentiated (n = 15) tumors (Figure 2 and Additional file 1:
Figure S1b). Significant differences in R-RAS2 expression
were observed depending of the type and origin of the
tumor, with the strongest R-RAS2 expression detected in
medulloblastomas and the weakest in undifferentiated
ependymoma (Figure 2).
Table 1 Samples obtained from a commercial brain
Histo-Pathology Grade1 Patients Samples Mean age Men (%)
a) Clinicopathologic data of 193 human CNS samples
Brain tissue - 13 23 35,3 ± 19,2 38,5
Hyperplasia - 2 3 34,7 ± 8,1 50
Mixed glioma - 2 4 41 ± 3,5 100
Glioblastoma III 7 13 60,5 ± 14,4 85,7
IV 9 15 49,5 ± 16,9 66,6
Astrocytoma I 32 59 37,6 ± 10,3 69,6
II 28 54 43,5 ± 14,2 60,7
III 5 9 44,4 ± 7,3 20
Oligodendroglioma I-II 2 4 29,5 ± 0,6 50
II-III 3 5 57,4 ± 15,1 100
III 2 4 42,5 ± 11 100
b) Clinicopathologic data of 56 human CNS tumor samples
Medulloblastoma IV 6 18 8,8 ± 5 66,6
Cerebroma IV 3 9 26,6 ± 16,9 33,3
Meningioma IV 4 11 40 ± 9,5 75
Ependymoma IV 1 3 14 ± 0 100
Undifferenciated IV 5 15 11,2 ± 4 60
Histo-Pathology Grade1 Patients Mean age Men (%)
c) Clinicopathologic data of 32 human CNS samples
Brain tissue - 1 55 0
Hyperplasia - 1 45 ± 0 100
Astrocytoma I 1 27 ± 0 0
II 2 39,5 ± 19,1 50
III 3 35 ± 4,6 100
Oligoastrocytoma II 1 37 ± 0 0
III 1 41 ± 0 100
Oligodendroglioma II 1 33 ± 0 100
III 3 45,3 ± 5,1 0
Ependymoma III 1 49 ±0 0
Meningioma I 13 53,8 ± 13,6 38,5
II 4 61 ± 11,2 50
1Classified according to the WHO criteria.
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RRAS2 overexpression in human CNS tumors was con-
firmed by RT-qPCR in tissue samples from 32 patients
(Table 1c). In different brain tumor types, RRAS2 mRNA
expression was 2- to 22-fold higher than in normal tissue
(Figure 3a). The highest levels of expression were found in
grade II astrocytomas (22-fold increase, n = 2), whereas 4-
fold increases were detected in grade III astrocytomas (n =
3), confirming that RRAS2 is more strongly overexpressed
in lower-grade tumors. RRAS2 mRNA overexpression was
also detected in pre-malignant hyperplasia (a 16-fold in-
crease, n = 1: Figure 3a and Additional file 3: Figure S2). The
only exception was a grade I astrocytoma sample in whichlow RRAS2 mRNA levels were detected (n = 1), although
this may have been due to misclassification. even though
the number of mRNA samples classified by tumor type was
not sufficiently high to generate statistically significant dif-
ferences, the mRNA expression data supported the protein
expression results. However, when the tumors were grouped
together in function of their degree of malignancy (grade I,
n = 13; grade II, n = 8; and grade III, n = 8) statistically sig-
nificant differences in expression were observed (Figure 3d).
Confirmation of R-RAS2 expression in western blots
We analyzed the expression of R-RAS2 in western blots
of low grade (n = 5) and high grade (n = 5) malignant
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Figure 1 R-RAS2 protein expression in human CNS tumors. Samples were obtained from the commercial Brain Tumor Screen tissue
microarray (CC17-11-004). Cryostat sections of human brain tissue (from normal brain, hyperplasias, glioblastoma grade III or IV, astrocytoma
grades I, II or III, and oligodendroglioma grades I, II or III) were analyzed by immunostaining with antibodies against R-RAS2, and they were
counterstained with hematoxylin and eosin. A quantitative analysis of R-RAS2 expression was performed for each brain tumor subtype,
normalizing the R-RAS2 values to the levels expressed in normal tissue. R-RAS2 protein expression is represented as the diaminobenzidine
absorbance, which reflects the presence of the protein in the samples. Student’s t-test *p < 0.05, **p < 0.0005, ***p < 0.00005. ANOVA p < 0.00001.
Scale bars = 50 μm.
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http://www.molecular-cancer.com/content/12/1/127astrocytomas (Table 2). The results obtained indicate the
existence of R-RAS2 overexpression associated with tumor
progression as opposed to the control tissue (n = 3). Fur-
thermore, stronger expression was observed in tumors with
a lower degree of malignancy (Figure 4a and b). These data
confirm the results obtained previously by immunohisto-
chemistry and RT-qPCR, where R-RAS2 was seen to beexpressed more strongly in the lower grade tumors as op-
posed to the higher grade tumors (p < 0.05; Figure 4b).
In CNS tumors, R-RAS2 is the most strongly
overexpressed gene within the R-RAS subfamily
RRAS2 gene expression was compared by qPCR with that
of the other 2 genes in this R-RAS subfamily (RRAS1 and
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Figure 2 Expression of R-RAS2 protein in tissue from highly malignant human CNS tumors. Samples were obtained from the commercial
Brain Medulloblastoma tissue microarray (CC17-01-002). Cryostat sections of human brain tumor tissue from medulloblastomas, cerebromas,
meningiomas, ependymomas and undifferentiated tumor tissue were immunostained with an antiserum against R-RAS2, and counterstained with
hematoxylin and eosin. R-RAS2 expression is represented as the diaminobenzidine absorbance in the samples, and R-RAS2 expression in each
brain tumor subtypes was quantified and normalized to the expression in control samples Student’s t-test *p < 0.05, **p < 0.00005. ANOVA
p < 0.00001. Scale bars = 50 μm.
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observed a general increase in RRAS1 mRNA in CNS tu-
mors and a decrease in RRAS3 expression in CNS tumors
(Figure 3b, Additional file 3: Figure S2 and Table 3). When
we assessed RRAS1, RRAS2 and RRAS3 expression ac-
cording to tumor type and grade (Figure 3b-d), the expres-
sion of RRAS1 and RRAS2, but not that of RRAS3, was
significantly stronger in grade I and II tumors than in
grade III tumors (p < 0.01). However, while RRAS2 over-
expression in grade I tumors was 13-fold higher than in
normal tissue, RRAS1 levels only experienced a 5-fold in-
creased (Figure 3b-e).
Discussion
This is the first study to demonstrate that R-RAS2 is
overexpressed in a wide variety of human CNS tumors.
R-RAS2 was overexpressed in all the tumors analyzed
when compared with normal tissue, and significantly
stronger expression was detected in low-grade as opposed
to high-grade tumors. Hence, R-RAS2 overexpression
seems to be associated with the early stages of transform-
ation and indeed, R-RAS2 overexpression was also associ-
ated with gliosis and hyperplasia, both of which are
considered to be pre-malignant processes. When the ex-
pression of mRNA encoding the other 2 members of the
RAS-related subfamily was assessed, the brain specific
RRAS3 was not overexpressed in CNS tumors. By con-
trast, RRAS1 mRNA expression was enhanced in CNS tu-
mors, albeit not to the same extent as RRAS2. Given thatunlike RRAS1 or RRAS3, RRAS2 can transform NIH-3 T3
cells [8-11], and in light of the low frequency of oncogenic
mutations in classic Ras genes, we hypothesize that
R-RAS2 overexpression is an important event in the trans-
formation of neural cells, particularly those that do not
carry oncogenic RAS mutations (database reference).
Nevertheless, further studies will be necessary to demon-
strate this assumption.
There is compelling evidence that R-RAS2 activity is
linked to the activation of the PI3K pathway. Indeed,
R-RAS2 directly recruits and activates several catalytic
subunits of type I PI3K [23,24]. In conjunction, these data
suggest that by activating the PI3K pathway, R-RAS2 can
promote neural cell survival and proliferation in association
with transformation in several types of CNS cancers. This
hypothesis is consistent with the high frequency of inacti-
vating or deleting mutations in PTEN, a negative regulator
of PI3K activity, in brain tumors [25-27].
One of the principal causes of cancer are increases in
PTEN-PI3K signaling [28] given that mutations in PI3K
or PTEN that maintain these proteins active induce
tumorigenic processes [29,30]. In the CNS in particular,
PTEN and PI3Kα appear among the 15 genes most
frequently mutated in tumors (Cosmic database, Sanger
Institute), irrespective of their location and histological
type. Nevertheless, the frequency with which mutations
appear in PTEN/PI3K does increase in function of the
malignancy of the tumor. Thus, for example, the fre-
quency of mutations in PTEN increases from 1% in
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Figure 3 RRAS2 fulfils an important role in low grade tumors. a) A qPCR analysis of the cDNA obtained from different human brain samples
from the commercial Brain Cancer cDNA Array I (HBRT102) was performed using specific oligos. The mean expression of RRAS2 mRNA is shown
for each tumor subtype and grade, and all the values shown are relative to the expression of RRAS2 mRNA in healthy tissue. b-e) The expression
of all RRAS subfamily members is altered in tumor cells. A qPCR analysis of the cDNAs from human brain tumors represented according to the
tumor type. RRAS1, RRAS2 and RRAS3 transcripts were measured in each sample from the Brain Cancer cDNA Array I (HBRT102). c-e) Transcript
levels of the different R-RAS subfamily members were gather and analyzed according to the degree of malignancy (WHO criteria), normalizing all
the data relative to the expression in healthy tissue. Student’s t-test *p < 0.05, **p < 0.01. ANOVA p < 0.05.
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Table 2 Clinical data of different grade astrocytomas
analyzed in western blots
Histo-pathology Grade1 Patients Samples Mean age Men (%)
Brain tissue - 3 3 41,3 ± 37 33,3
Astrocitoma II 5 5 44 ± 10 40
Glioblastoma IV 5 5 66,6 ± 13 40
1Classified according to the WHO criteria.
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http://www.molecular-cancer.com/content/12/1/127grade I astrocytomas to 21% in grade IV astrocytomas.
Likewise, PI3K does not appear to be mutated in low
grade astrocytomas but the frequency of mutations in
high grade malignant tumors of this type reaches 6%.
The same occurs in oligodendrogliomas in which the
frequency of mutations in PTEN and PI3Kα is 3-2% in
low grade tumors, reaching 4 and 10%, respectively, in
high grade tumors (Cosmic database, Sanger Institute).
Alternatively, activating mutations and overexpression
of classical Ras subfamily members have been described
as elements responsible for the development of tumors
in human [3], although only 0.5% of CNS tumors
present mutations in classical RAS. Indeed, mutations in0
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Figure 4 Increased R-RAS2 expression in astrocytomas. a) R-RAS2 and
astrocytoma (n = 5) and grade IV astrocytoma (n = 5) analyzed in Western b
to the amount of protein in the control, grade II and IV astrocytomas. Stud
R-RAS2 at different tumor stages.RRAS2 have not been found in the CNS (n = 7,378: Cos-
mic database, Sanger Institute). Given the above, we
propose that the overexpression of R-RAS2 may be an
important event in the initiation of the neural trans-
formation process in low grade CNS tumors, in which
the PTEN/PI3K pathway has still to be activated due to
mutation.Conclusions
Our findings demonstrate that R-RAS2 mRNA and pro-
tein is overexpressed in a wide variety of human CNS
tumors, including glioblastomas, astrocytomas, oligo-
dendrogliomas and medulloblastomas. While R-RAS2
was overexpressed in all CNS tumor types, its expression
was inversely related to the degree of malignancy,
suggesting that R-RAS2 overexpression is an early event
in neural cell transformation.Ethical standards
This study was performed in compliance with all applic-
able European and Spanish law.ontrol
 Grade
 Grade
GAPDH expression in lysates of control brain tissue (n = 3), grade II
lots. b) Graph show the mean and SD of the signal quantified relative
ent’s t-test p < 0.005. c) Diagram showing the hypothesis of the role of
Table 3 RT-qPCR results mean fold variation for RRas1, RRas2 and RRas3
RRas1 RRas2 RRas3
Histo-pathology Grade1 Gender Age Fold
variation2
Standard
deviation3
Fold
variation2
Standard
deviation3
Fold
variation2
Standard
deviation3
Brain tissue - Female 55 1,003 0,151 1,000 0,150 1,000 0,150
Meningioma, fibroblastic I Female 56 3,054 1,004 3,596 1,183 0,254 0,083
Meningioma, fibroblastic I Female 51 7,878 0,335 - - 0,522 0,022
Meningioma I Male 71 2,106 0,181 19,016 1,632 1,040 0,089
Meningioma,
meningothelial
I Female 56 4,565 1,672 8,514 3,118 0,262 0,096
Meningioma, secretory I Female 41 1,422 0,160 25,092 2,825 0,083 0,009
Meningioma I Female 42 5,798 1,248 4,779 1,029 0,263 0,057
Meningioma, fibroblastic I Male 39 - - 13,533 4,059 0,592 0,178
Meningioma, fibroblastic I Male 43 1,944 0,640 14,801 4,873 0,133 0,044
Astrocytoma I Female 27 4,550 0,691 2,253 0,342 - -
Meningioma I Female 83 3,043 0,414 10,352 1,407 0,251 0,034
Meningioma I Male 68 3,027 1,174 6,131 2,378 0,202 0,078
Meningioma I Female 45 6,406 5,394 2,441 2,056 0,526 0,443
Meningioma I Female 61 4,791 0,024 8,719 0,043 0,352 0,002
Meningioma I Male 44 5,386 0,485 10,301 0,927 0,688 0,062
Meningioma, atypical II Male 67 2,365 0,154 14,736 0,962 0,103 0,007
Hyperplasia II Male 45 0,636 0,043 14,934 1,004 0,075 0,005
Oligoastrocytoma II Female 37 - - 6,902 3,282 - -
Astrocytoma II Male 26 0,503 0,156 21,775 6,753 0,058 0,018
Meningioma,
meningothelial
II Female 56 2,388 1,323 4,122 2,284 0,312 0,173
Astrocytoma II Female 53 0,928 0,287 22,939 7,099 0,042 0,013
Meningioma, atypical II Male 73 1,757 1,006 7,157 4,096 0,129 0,074
Meningioma, atypical II Female 48 4,151 1,897 4,118 1,882 0,512 0,234
Oligodendroglioma II Male 33 1,545 0,269 10,723 1,868 0,211 0,037
Astrocytoma, anaplastic III Male 36 1,768 0,583 2,815 0,929 0,403 0,133
Astrocytoma, anaplastic III Male 39 1,290 0,236 0,559 0,102 0,702 0,128
Astrocytoma III Male 30 1,721 0,875 8,782 4,464 0,128 0,065
Oligodendroglioma,
anaplastic
III Female 41 0,814 0,185 0,579 0,131 - -
Ependymoma of brain,
anaplastic
III Female 49 0,895 0,055 2,548 0,155 0,266 0,016
Oligoastrocytoma,
anaplastic
III Male 41 1,211 0,175 3,254 0,470 0,432 0,062
Oligodendroglioma,
anaplastic
III Female 51 0,521 0,075 5,038 0,721 0,165 0,024
Oligodendroglioma,
anaplastic
III Female 44 1,707 0,509 7,080 2,110 0,119 0,035
1Classified according to the WHO criteria.
2All results were calculated as the mean of the three measurements performed on each sample and subsequently normalized to the expression in the non
tumoral sample.
3Standard deviation of the three measurements performed on each sample.
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Additional file 1: Figure S1. a) Combined R-RAS2 expression levels
in all samples from a brain tumor tissue microarray. R-RAS2 protein
levels were expressed as the diaminobenzidine absorbance that reflects
the presence of the protein in the samples. The R-RAS2 in human brain
tissue is expressed relative to that found in healthy brain samples. All
values were normalized to the levels detected in control tissue and the
error bars are due to technical errors. All samples were derived from
different human CNS tumors obtained from a commercial array (CC17-
11-004). b) Combined R-RAS2 expression in samples from a brain
tissue microarray. R-RAS2 protein levels expressed as the
diaminobenzidine absorbance that reflects the presence of the protein in
the samples. All samples were derived from different grade IV human
CNS tumors obtained from a commercial brain medulloblastoma
TMA (CC17-01-002). The error bars are due to technical errors.
c) Confirmation of anti-R-RAS2 specificity. In Western blots the
antiserum raised against R-Ras2 identified the protein in total brain
samples but not in lysates from mutant RRas2−/− mice. As a loading
control, the same aliquots were probed with anti-α tubulin antibodies
(bottom).
Additional file 2: Figure S3. R-RAS2 protein expression in different
grades of tumors. Representative photographs of each tumor from the
Brain Tumor Screen Tissue microArray (CC17-11-004) after the array was
analyzed by immunostaining with anti-R-RAS2, and counterstained with
hematoxylin and eosin. LA, Little Astrocytoma; HG, Hyperplasia of
gliocyte; A, Astrocytoma; and O, Oligodendroglioma.
Additional file 3: Figure S2. Combined results of the qPCR analyses.
The cDNAs assayed were derived from different human brain samples
obtained from a commercial cancer cDNA array (HBRT102). The samples
were analyzed using specific oligos for RRAS1, RRAS2 and RRAS3 mRNA.
RRAS1 (a), RRAS2 (b) and RRAS3 (c) mRNA expression in tumor tissues and
hyperplastic samples was normalized to β-actin expression, and the data
are expressed relative to the mRNA expression in healthy tissue. The error
bars are due to technical errors.
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